WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options
Portfolio Pulse from Benzinga Newsdesk
The World Health Organization (WHO) has expanded its emergency use list for Mpox diagnostics by adding Cepheid's Xpert Mpox PCR test and Roche's Cobas MPXV assay as PCR-based gold standard options.
October 30, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cepheid's Xpert Mpox PCR test has been recognized by the WHO as a gold standard option for Mpox diagnostics, potentially boosting its market presence.
Cepheid's Xpert Mpox PCR test being added to the WHO's emergency use list could increase its adoption and sales, likely benefiting Cepheid's financial performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's Cobas MPXV assay has been added to the WHO's emergency use list for Mpox diagnostics, positioning it as a gold standard PCR-based option.
The inclusion of Roche's Cobas MPXV assay in the WHO's emergency use list enhances its credibility and could lead to increased demand for the product, positively impacting Roche's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80